Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL5116397 | 0.88 | DRD2 (0.38) | MAPTTRPA1TRPV1MALT1DRD2 | |
| SCHEMBL1457231 | 0.85 | TRPV1 (0.50) | TRPA1TRPV1RBP4L3MBTL1 | |
| Formamide SCHEMBL5122603 | 0.80 | CXCR3 (0.40) | TRPV1L3MBTL1KMT2A | |
| SCHEMBL5127608 | 0.74 | TRPV1 (0.54) | TRPA1TRPV1RBP4 | |
| SCHEMBL1457235 | 0.74 | TRPV1 (0.48) | TRPA1TRPV1MALT1 | |
| SCHEMBL1457227 | 0.73 | P2RY12 (0.45) | TRPA1TRPV1LMNAKMT2A | |
| SCHEMBL5117962 | 0.73 | P2RY12 (0.51) | TRPA1TRPV1RBP4 | |
| SCHEMBL1457447 | 0.73 | TRPA1 (0.45) | TRPA1TRPV1MALT1RBP4 | |
| SCHEMBL1457424 | 0.71 | TRPA1 (0.43) | ALDH1A1TRPA1TRPV1MALT1RBP4 | |
| SCHEMBL5127551 | 0.70 | RBP4 (0.62) | TRPA1TRPV1MALT1RBP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | claimed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | MAPT 3811/4885ALDH1A1 281/4885TRPA1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.